NCT02688894Recruiting
The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]
Source: ClinicalTrials.gov · Last updated 12 Aug 2026
Brief summary (registry, in English)
This protocol is a molecular screening protocol only. No drug intervention study will be included in this protocol. Based on the molecular profiling, patients may be eligible for drug intervention study of SUKSES trial. This procedure can be performed during or after the first-line treatment. DNA will be extracted from the archived or fresh tissue and blood. NGS-based cancer panel and Nanostring CNV will be tested with DNA from tissue and/or blood. Immunohistochemistry and FISH will be done by pathologists using archived or fresh tissue. Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH. Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 797 (estimated)
- First submitted
- 18 Feb 2016
- Start date
- 10 Jun 2016
- Primary completion date
- Sept 2028
- Lead sponsor
- Samsung Medical Center
- Diseases
- Neuroendocrine tumours, Lung cancer
- NCT number
- NCT02688894
What you commit to
- Study type: Observational
- Planned participants: 797
- From 10 Jun 2016 to the primary completion date, Sept 2028
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- More than two prior chemotherapy regimen for the treatment of small cell lung cancer
- Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≤2 years.
Other
- Pregnant or nursing women (women of reproductive potential have to agree to use an effective contraceptive method)
Who the study is looking for
- Provision of fully informed consent prior to any study specific procedures.
- Patients must be ≥20 years of age.
- Histologically or cytologically confirmed Small cell lung cancers
- ECOG performance status of 0 to 2
- Patients who are being treated or were treated with platinum-based chemotherapy as a first-line treatment
- Patients with available archival tissues for molecular analysis or patients who agreed with biopsy for molecular analysis
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gachon University Gil Medical Center Coordinator of this site? Confirm its status | Incheon | South Korea | Completed |
| Chungbuk University Hospital Coordinator of this site? Confirm its status | Jungbuk | South Korea | Completed |
| Seoul National University Bundang Hospital Coordinator of this site? Confirm its status | Seongnam | South Korea | Completed |
| VHS Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Completed |
| Samsung Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
| Ulsan University Hospital Coordinator of this site? Confirm its status | Ulsan | South Korea | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.